Articles from biomodal

biomodal, an omics-based life sciences technology and analytics company, today announced it has filed a lawsuit against Watchmaker Genomics (“Watchmaker”) in the United States District Court for the District of Colorado. The lawsuit seeks damages and a court order to stop Watchmaker from making, using, selling, or offering for sale their TAPS+ product, or otherwise infringing on patents exclusively licensed by biomodal from Boston Children’s Hospital through Children’s Medical Center Corporation (“CMCC”), as outlined in the complaint.

biomodal, an omics-based life sciences technology and analytics company, today announced it has launched a Certified Service Provider (CSP) program with partners around the globe to meet the increasing demand for its novel duet multiomics solutions. The organizations are partnering with biomodal as they work to deliver transformative data and insights for researchers in areas such as disease detection and therapy selection and monitoring, as well as providing mechanistic insights into disease.

biomodal, an omics-based life sciences technology and analytics company, today announced it will present new data highlighting the utility of duet multiomics solution evoC in the early detection of disease by distinguishing 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) to synergistically increase signal. As described in a recently submitted preprint, the 6-base genome – A, T, G, C, 5mC, and 5hmC – enables the observation of an elevated 5hmC signal in the early stages of disease which precedes the loss of 5mC in later stage disease.

biomodal, an omics-based life sciences technology and analytics company, today announced it has filed a lawsuit against New England Biolabs (“NEB”) in the United States District Court for the District of Massachusetts. The lawsuit seeks damages and a court order to stop NEB from making, using, selling, or offering for sale all NEBNext® Enzymatic 5hmC-seq products, and NEBNext® Enzymatic Methyl-seq products in clinical markets, or otherwise infringing on patents exclusively licensed by biomodal from Boston Children’s Hospital through Children’s Medical Center Corporation (“CMCC”), as outlined in the complaint.

biomodal, an omics-based life sciences technology and analytics company, today announced it is delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet evoC). The combinatorial genetic and epigenetic technology provides single-base-resolution sequencing data that reveals standard four-base sequencing (A, G, C, and T), and distinguishes between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), on the same DNA molecule. This added resolution will allow greater power in detecting disease associations, identifying novel biomarkers, developing disease classifiers, and monitoring the progression of disease; even with limited samples such as cell-free DNA (cfDNA).